Hetty Carraway, MD, describes how MDS differs from acute myeloid leukemia (AML), and the percentage of patients who progress to AML from MDS.
Novel Approaches Focus on Limiting Toxicity in Older Patients With ALL
April 22nd 2024The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Read More